Quinidine

Generic Name
Quinidine
Brand Names
Nuedexta
Drug Type
Small Molecule
Chemical Formula
C20H24N2O2
CAS Number
56-54-2
Unique Ingredient Identifier
ITX08688JL
Background

Quinidine is a D-isomer of quinine present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus r...

Indication

Quinidine is indicated for the management and prophylactic therapy of atrial fibrillation/flutter, as well as the suppression of recurrent documented ventricular arrhythmias. It is also used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation..

Associated Conditions
Atrial Fibrillation or Flutter, Malaria caused by Plasmodium falciparum, Pseudobulbar Affect (PBA), Ventricular Arrhythmia
Associated Therapies
-
Clinical Trials
Related News

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

First Posted Date
2012-10-24
Last Posted Date
2019-11-08
Lead Sponsor
Celgene
Target Recruit Count
31
Registration Number
NCT01712828
Locations
🇺🇸

Covance Clinical Research Unit Dallas, Dallas, Texas, United States

Nuedexta for the Treatment of Adults With Autism

Phase 2
Completed
Conditions
Autism
Interventions
Other: Placebo
Drug: Nuedexta
First Posted Date
2012-06-28
Last Posted Date
2017-12-08
Lead Sponsor
Sutter Health
Target Recruit Count
13
Registration Number
NCT01630811
Locations
🇺🇸

Sutter Pediatric Neurology, Sacramento, California, United States

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

First Posted Date
2012-02-15
Last Posted Date
2014-10-15
Lead Sponsor
AstraZeneca
Target Recruit Count
214
Registration Number
NCT01533155
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

A Study to Evaluate the Effect of Genotype on LY2216684

Phase 1
Completed
Conditions
Depressive Disorder, Major
Interventions
Drug: LY2216684
Drug: Quinidine
First Posted Date
2011-10-26
Last Posted Date
2018-10-26
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
18
Registration Number
NCT01460381
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Empiric Quinidine for Asymptomatic Brugada Syndrome

Phase 2
Withdrawn
Conditions
Arrhythmia
Interventions
Drug: quinidine
Drug: no therapy
First Posted Date
2008-11-11
Last Posted Date
2020-02-13
Lead Sponsor
International Registry of Asymptomatic Brugada Syndrome
Registration Number
NCT00789165
Locations
🇳🇱

Academic Medical Centre, Amsterdam, Netherlands

🇮🇱

Tel Aviv Medical Center, Tel Aviv, Israel

🇯🇵

National Cardiovascular Center, Osaka, Japan

and more 3 locations

Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

First Posted Date
1999-10-28
Last Posted Date
2016-03-25
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Registration Number
NCT00000556

Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)

First Posted Date
1999-10-28
Last Posted Date
2013-07-29
Lead Sponsor
University of Washington
Registration Number
NCT00000464

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)

First Posted Date
1999-10-28
Last Posted Date
2016-01-21
Lead Sponsor
University of Utah
Registration Number
NCT00000518
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy